Dabigatran etexilate Recruiting Phase 4 Trials for Valve Heart Disease / Nonvalvular Atrial Fibrillation Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02982850Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
NCT02666157Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
NCT02331602Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran